Views
5 years ago

110 - D Serrani - Agosto 2018

  • Text
  • Accion
  • Farmacoterapia
  • Serrani
  • Serrani
  • Peso
  • Pacientes
  • Aumento
  • Tratamiento
  • Efectos
  • Obesidad
  • Diabetes
  • Dosis
  • Corporal
Enfermedad mental, sobrepeso, obesidad y su tratamiento. Parte 2. Dr. Daniel Serrani

Dr. Daniel

Dr. Daniel Serrani tolerability in overweight and obese women. Obesity Research 2001, 9(9), 544-551. • 27. Volkow ND, Wang GJ, Fowler JS, Logan J, Jayne M, Franceschi D & Pappas N. “Nonhedonic” food motivation in humans involves dopamine in the dorsal striatum and methylphenidate amplifies this effect. Synapse 2002, 44(3), 175-180. • 28. Krude H, Biebermann H, Schnabel D, Tansek MZ, Theunissen P, Mullis PE & Grüters A. Obesity due to proopiomelanocortin deficiency: three new cases and treatment trials with thyroid hormone and ACTH4–10. The Journal of Clinical Endocrinology & Metabolism 2003, 88(10), 4633-4640. • 29. Barak N. Betahistine: what’s new on the agenda? Expert opinion on investigational drugs 2008, 17(5), 795-804. • 30. Halford JC, Boyland EJ, Blundell JE, Kirkham TC & Harrold JA. Pharmacological management of appetite expression in obesity. Nature Reviews Endocrinology 2010, 6(5), 255. • 31. Aotani D, Son C, Shimizu Y, Nomura H, Hikida T, Kusakabe T & Nakao K. Reevaluation of anti-obesity action of mazindol and elucidation of its effect on the reward system. Neuroscience Letters 2016, 633, 141-145. • 32. Kernan WN, Viscoli CM, Brass LM, et al. Phenylpropanolamine and the risk of hemorrhagic stroke. N Engl J Med 2000; 343: 1826-32. • 33. Shin JH & Gadde KM. Clinical utility of phentermine/topiramate (Qsymia) combination for the treatment of obesity. Diabetes Metab Syndr Obes 2013, 6, 131-139. • 34. Hendricks EJ, Srisurapanont M, Schmidt SL, et al. Addiction potential of phentermine prescribed during long-term treatment of obesity. Int J Obes (Lond). 2014; 38:292–298. • 35. Hampp C, Kang EM, Borders-Hemphill V. Use of prescription antiobesity drugs in the United States. Pharmacotherapy 2013; 33: 1299-1307. • 36. Cercato C, Roizenblatt VA, Leança CC, et al. A randomized double-blind placebo controlled study of the long-term efficacy and safety of diethylpropion in the treatment of obese subjects. Int J Obes (London) 2009; 33: 857-65. • 37. Haddock CK, Poston WS, Dill PL, Foreyt JP, Ericsson M. Pharmacotherapy for obesity: a quantitative analysis of four decades of published randomized clinical trials. Int J Obes Relat Metab Disord 2002; 26: 262-73. • 38. Cosentino, G., Conrad, A. O., & Uwaifo, G. I. (2013). Phentermine and topiramate for the management of obesity: a review. Drug design, development and therapy, 7, 267. • 39. Haddock CK, Poston WS, Dill PL, Foreyt JP, Ericsson M. Pharmacotherapy for obesity: a quantitative analysis of four decades of published randomized clinical trials. Int J Obes Relat Metab Disord 2002; 26: 262-73. • 40. Schulz, L.O.; Bennett, P.H.; Ravussin, E.; Kidd, J.R.; Kidd, K.K.; Esparza, J.; Valencia, M.E. Effects of traditional and western environments on prevalence of type 2 diabetes in Pima Indians in Mexico and the U.S. Diabetes Care, 2006, 29, 1866-71. • 41. Fidler MC, Sanchez M, Raether B, et al. A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial. J Clin Endocrinol Metab. 2011; 96:3067–3077. • 42. Smith SR, Weissman NJ, Anderson CM, et al. Multicenter, placebo- controlled trial of lorcaserin for weight management. N Engl J Med. 2010; 363:245–256. • 43. O’Neil PM, Smith SR, Weissman NJ, et al. Randomized placebocontrolled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study. Obesity 2012; 20:1426–1436. • 44. Serrani D. Efecto de betahistina sobre aumento de peso inducido por quetiapina. Revista psicofarmacología 2016 98:11. • 45. Fanghänel G, Cortinas L, Sánchez-Reyes L, Berber A. Second phase of a double-blind study clinical trial on Sibutramine for the treatment of patients suffering essential obesity: 6 months after treatment cross-over. Int J Obes Relat Metab Disord. 2001; 25;741–747. • 46. Anderson JW, Schwartz SM, Hauptman J, et al. Low-dose orlistat effects on body weight of mildly to moderately overweight individuals: a 16 week, double-blind, placebo-controlled trial. Ann Pharmacother. 2006; 40:1717–1723. • 47. Xenical (orlistat) [prescribing information]. South San Francisco, CA: Genentech USA Inc. http://www.gene.com/download/pdf/xenical_prescribing. pdf. Consultado Mayo 2, 2016. • 48. Alli (orlistat) [label]. Moon Township, PA: GlaxoSmithKline. http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021887lbl.pdf. Consultado Mayo 2, 2016. • 49. Malin SK, Kashyap SR. Effects of metformin on weight loss: potential mechanisms. Curr Opin Endocrinol Diabetes Obes. 2014; 21(5):323–329. • 50. Caton PW, Kieswich J, Yaqoob MM, Holness MJ, Sugden MC. Metformin opposes impaired AMPK and SIRT1 function and deleterious changes in core clock protein expression in white adipose tissue of genetically-obese db/db mice. Diabetes Obes Metab 2011; 13 (12):1097–1104. • 51. Hollander P, Raslova K, Skjøth TV, Råstam J, Liutkus JF. Efficacy and safety of insulin detemir once daily in combination with sitagliptina and metformin: the TRANSITION randomized controlled trial. Diabetes Obes Metab. 2011; 13:268–275. • 52. McIntosh B, Cameron C, Singh SR, et al. Second-line therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a systematic review and mixed-treatment comparison meta-analysis. Open Med. 2011; 5:e35–e48. • 53. Wu D, Li L, Liu C. Efficacy and safety of dipeptidyl peptidase-4 inhibitors and metformin as initial combination therapy and as monotherapy in patients with type 2 diabetes mellitus: a meta-analysis. Diabetes Obes Metab. 2014; 16(1):30–37. • 54. Wainstein J, Katz L, Engel SS, et al. Initial therapy with the fixeddose combination of sitagliptin and metformin results in greater improvement in glycaemic control compared with pioglitazone monotherapy in patients with type 2 diabetes. Diabetes Obes Metab. 2012; 14(5):409–418. • 55. Bolinder J, Ljunggren Ö, Kullberg J, et al. Effects of dapagliflozina on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab. 2012; 97:1020–1031. • 56. Buse JB, Bergenstal RM, Glass LC, et al. Use of twice-daily exenatida in basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial. Ann Intern Med. 2011; 154:103–112. • 57. Aronne L, Fujioka K, Aroda V, Chen K, Halseth A, Kesty NC & Weyer C. Progressive reduction in body weight after treatment with the amylin analog pramlintide in obese subjects: a phase 2, randomized, placebo-controlled, dose-escalation study. The Journal of Clinical Endocrinology & Metabolism 2007, 92(8), 2977-2983. • 58. van de Laar FA, Lucassen PL, Akkermans RP. Alpha-glucosidase inhibitors for patients with type 2 diabetes: results from a Cochrane systematic review and meta-analysis. Diabetes Care. 2005; 28 (1):154–163. • 59. Lee A, Patrick P, Wishart J, Horowitz M, Morley JE. The effects of miglitol on glucagon-like peptide-1 secretion and appetite sensations in obese type 2 diabetics. Diabetes Obes Metab. 202; 4(5): 329–335. • 60. Wu D, Li L, Liu C. Efficacy and safety of dipeptidyl peptidase-4 inhibitors and metformin as initial combination therapy and as monotherapy in patients with type 2 diabetes mellitus: a meta-analysis. Diabetes Obes Metab. 2014; 16 (1): 30–37. • 61. Wainstein J, Katz L, Engel SS, et al. Initial therapy with the fixed dose combination of sitagliptin and metformin results in greater improvement in glycaemic control compared with pioglitazone monotherapy in patients with type 2 diabetes. Diabetes Obes Metab. 2012; 14(5):409–418. • 62. Richter B, Bandeira-Echtler E, Bergerhoff K, Lerch CL. Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2008; 2:CD006739. • 63. Scheen AJ. DPP-4 inhibitors in the management of type 2 diabetes: a critical review of head-to-head trials. Diabetes Metab. 2012; 38: 89–101. • 64. Bolinder J, Ljunggren Ö, Kullberg J, et al. Effects of dapagliflozina on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab 2012; 97: 1020–1031. • 65. Grandy S, Hashemi M, Langkilde AM, Parikh S, Sjöström CD. Changes in weight loss-related quality of life among type 2 diabetes mellitus patients treated with dapagliflozin. Diabetes Obes Metab 2014; 16: 645–650. 16 // EDITORIAL SCIENS

Biblioteca

Av. García del Río 2585 Piso 12 A - C.A.B.A
+54 11 2092 1646 | info@sciens.com.ar

Editorial Sciens, Todos los Derechos Reservados 2015